As of December 31, 2022, the Company had cash and cash equivalents and marketable securities of approximately $26.4 million. "With the initiation of our INDP-D101 trial at the end of December 2022 and the subsequent dosing of our first patient in the first cohort, we are well underway in our Phase 1 trial of Decoy20 for the treatment of solid tumors," said Jeffrey Meckler, chief executive officer of Indaptus. "Following the initial dosing we were encouraged to learn that the subject experienced manageable and expected adverse events related to the immune response we anticipated. We are looking forward to analyzing the data generated from that first patient and finishing the first arm of the trial per the protocol. As we continue to bring new centers online and enroll patients, we will continue to prudently manage our cash position, and update stakeholders on our progress as it develops."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on INDP:
- Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
- Indaptus Therapeutics activates Emory Winship Cancer Institute as trial site
- Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
- Indaptus Therapeutics doses first subject in ongoing Phase 1 lab